Insulin Glulisine

France

URL Supplier Web Content

Patent Number

2441260

Strength per Unit

100 U / mL

Dosage Form

Solution

Human Or VET

Human

Patent Expiration Date

2022-03-09

Date Granted

2011-04-26

Filing Date

2002-03-09

Brand Name

APIDRA (3mL OptiSet)

Route of Administration

Subcutaneous Injection

CPhI Worldwide, Milan

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Sanofi-Aventis Canada Inc.

France

Insulin Glulisine

URL Supplier Web Content

Patent Number

2441260

Strength per Unit

100 U / mL (3mL Cartridge)

Dosage Form

Solution

Human Or VET

Human

Patent Expiration Date

2022-03-09

Date Granted

2011-04-26

Filing Date

2002-03-09

Brand Name

APIDRA

Route of Administration

Subcutaneous

CPhI Worldwide, Milan

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Sanofi-Aventis Canada Inc.

France

Insulin Glulisine

URL Supplier Web Content

Patent Number

2441260

Strength per Unit

100 U / mL (10 mL Vial)

Dosage Form

Solution

Human Or VET

Human

Patent Expiration Date

2022-03-09

Date Granted

2011-04-26

Filing Date

2002-03-09

Brand Name

APIDRA

Route of Administration

Subcutaneous

CPhI Worldwide, Milan

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Sanofi-Aventis Canada Inc.

France

Insulin Glulisine

URL Supplier Web Content

Patent Number

2441260

Strength per Unit

100 U / mL (3mL Solostar)

Dosage Form

Solution

Human Or VET

Human

Patent Expiration Date

2022-03-09

Date Granted

2011-04-26

Filing Date

2002-03-09

Brand Name

APIDRA

Route of Administration

Subcutaneous

CPhI Worldwide, Milan

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Sanofi-Aventis Canada Inc.

France

Insulin Glulisine

URL Supplier Web Content

Patent Number

2235443

Strength per Unit

100 U / mL

Dosage Form

Solution

Human Or VET

Human

Patent Expiration Date

2018-06-18

Date Granted

2011-11-01

Filing Date

1998-06-18

Brand Name

APIDRA (3mL OptiSet)

Route of Administration

Subcutaneous Injection

CPhI Worldwide, Milan

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Sanofi-Aventis Canada Inc.

France

Insulin Glulisine

URL Supplier Web Content

Patent Number

2235443

Strength per Unit

100 U / mL (3mL Cartridge)

Dosage Form

Solution

Human Or VET

Human

Patent Expiration Date

2018-06-18

Date Granted

2011-11-01

Filing Date

1998-06-18

Brand Name

APIDRA

Route of Administration

Subcutaneous

CPhI Worldwide, Milan

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Sanofi-Aventis Canada Inc.

France

Insulin Glulisine

URL Supplier Web Content

Patent Number

2235443

Strength per Unit

100 U / mL (10 mL Vial)

Dosage Form

Solution

Human Or VET

Human

Patent Expiration Date

2018-06-18

Date Granted

2011-11-01

Filing Date

1998-06-18

Brand Name

APIDRA

Route of Administration

Subcutaneous

CPhI Worldwide, Milan

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Sanofi-Aventis Canada Inc.

France

Insulin Glulisine

URL Supplier Web Content

Patent Number

2235443

Strength per Unit

100 U / mL (3mL Solostar)

Dosage Form

Solution

Human Or VET

Human

Patent Expiration Date

2018-06-18

Date Granted

2011-11-01

Filing Date

1998-06-18

Brand Name

APIDRA

Route of Administration

Subcutaneous

CPhI Worldwide, Milan

Attending